PDGFR.

Platelet-Derived Growth Factor Receptor (or Please Don’t Grow, For Real) is the novel target of some new systemic agents. Olaratumab is already making big headway in soft-tissue sarcoma and now dovitinib is going after castration-resistant prostate cancers.